News – Page 1106 – Endpoints News

Zealand bags a $77M IPO haul as investors embrace another biotech offering

8 years ago

Eyeing an IPO, Sutro retools its $1B I/O deal with Celgene but stays focused on BCMA

8 years ago

Can Novo’s blockbuster push on obesity drug semaglutide succeed where others failed?

8 years ago

Galapagos spotlights an 'exciting' round of PoC data for IPF drug, shares surge

8 years ago

Citing a ‘conflict,’ GSK vet Slaoui abruptly quits Intellia board

8 years ago

Ardelyx brings out the ax, chopping 28% of staffers; PRA bags Symphony Health Solutions in $530M acquisition

8 years ago

Orbimed partner in search of a cure for Parkinson’s launches new gene therapy player

8 years ago

Spurred by Gottlieb, FDA on track to the most generic drug OKs ever in 1 year

8 years ago

SoftBank bets $1.1B on Roivant CEO Vivek Ramaswamy’s brash new biotech strategy

8 years ago

Melinta will beef up its antibiotics pipeline after a merger with troubled Cempra

8 years ago

China biotech bags a $57M round as it races to complete R&D, manufacturing site

8 years ago

Trying to turn a new leaf, Valeant ‘blockbuster’ can’t shed an R&D jinx

8 years ago

Warring with ex-CEO, options shrinking, Aeterna Zentaris turns to a strategic review

8 years ago

Aclaris bags St. Louis biotech for $20M; Pfizer investing $100M in gene therapy work

8 years ago

Sanofi believes it’s still not too late to become a top player in cancer drug market

8 years ago

Esperion shares bounce up on an effective triplet approach to slashing LDL

8 years ago

Prepping for a rapid-fire launch, Kite Pharma gets a pass from FDA on axi-cel panel review

8 years ago

Roche sells off its struggling IL-13 drug lebrikizumab in $1.4B Dermira deal

8 years ago

Prepping for PhIII cancer study, Sellas reverse merges its way to a public listing

8 years ago

FibroGen shares rocket up on positive PhII data in idiopathic pulmonary fibrosis

8 years ago

FDA slams Vernalis with 2nd CRL in 3 months; Former Shkreli company KaloBios changes name

8 years ago

Updated: Acorda shares surge as a big investor pushes it to the auction block

8 years ago

Mallinckrodt bags late-stage infantile jaundice drug in $425M InfaCare buyout deal

8 years ago

Zynerba goes into meltdown mode as cannabis-derived drug flops in PhII

8 years ago

First page Previous page 1103 1104 110511061107 1108 1109 Next page Last page